The International Society for Pharmacoeconomics and Outcomes Research
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) will hold its 22nd Annual International Meeting in Boston, Massachusetts, from May 20-24, 2017. This year's meeting, Evidence and Value in a Time of Social and Policy Change, will bring payers, researchers, and other stakeholders together to learn about drug development and regulatory issues in today's rapidly-changing healthcare environment. Sign up for our daily e-mail blasts on our registration page, and check back here during the conference for the full coverage.
September 08, 2017
Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Centerís Postdoctoral Health Policy Fellow, discusses what needs to be included in the next generation of value assessment frameworks in order to best identify value that is representative of all patient preferences.
August 30, 2017
The United States can benefit from taking and adapting certain elements of European countriesí systems and methods of assessing value, says Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
August 23, 2017
A one-size-fits-all approach to value is impossible in the US healthcare system, but a pluralistic approach is extremely complex to implement, says Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Centerís Postdoctoral Health Policy Fellow.
August 16, 2017
A combination of different countriesí health systems can set an example for the United States to follow in efforts to restrain the ongoing increases in drug prices, explains Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
August 09, 2017
Patients, payers, and providers all view value in different ways, and they all need to be taken into account in value frameworks, said Ilene Hollin, PhD, MPH, the National Pharmaceutical Council and University of Southern California Schaeffer Centerís Postdoctoral Health Policy Fellow.
August 03, 2017
There are differences between cost effectiveness and affordability that people don't always understand. A drug may be cost effective but still not fall within the budget, explained Patricia Danzon, PhD, the Celia Moh Professor at The Wharton School, University of Pennsylvania.
July 28, 2017
Michael Sherman, MD, chief medical officer at Harvard Pilgrim Health Care, discusses the challenges of moving towards performance-based risk-sharing agreements and where they would work best for certain treatments.
July 25, 2017
Legislators from both parties may have difficulty finding a common solution to high drug prices, but President Donald Trump could be instrumental in bringing prices down if he acts on his pledges, according to David M. Cutler, PhD, of Harvard University.
July 23, 2017
Health technology assessment (HTA) is a tool that helps to objectively evaluate evidence, which levels the playing field for new therapies looking to demonstrate cost-effectiveness, according to Steve Pearson, MD, MSc, president of the Institute for Clinical and Economic Review. In doing so, stakeholders can better understand the balance between innovation and affordability.
July 16, 2017
Both political parties want to lower the price of drugs, but differ in how they think it should be done. Gail Wilensky, PhD, of Project HOPE, explained her opinion that spurring more competition would be a more successful approach than directly implementing price controls.